Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and compositions for treating lesions of the respiratory epithelium

A composition and technology of the respiratory tract, applied in the direction of respiratory diseases, drug combinations, botanical equipment and methods, etc., can solve problems such as increasing allergens and agonists, exacerbating inflammation and mucosal decomposition

Inactive Publication Date: 2005-05-18
THE GENERAL HOSPITAL CORP
View PDF7 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Additionally, in certain inflammatory states, such as asthma, disruption of the mucosa can lead to increased levels of allergens and agonists in order to further exacerbate inflammation and mucosal breakdown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for treating lesions of the respiratory epithelium
  • Methods and compositions for treating lesions of the respiratory epithelium
  • Methods and compositions for treating lesions of the respiratory epithelium

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0096] Example 1: Treatment of Rhinitis Caused by Rhinovirus

[0097] Immediately after the onset of the head cold, the patient was started to administer the trefoil-containing formulation. This formulation contains a therapeutic dose of ITF 15-73 . The trefoil peptide can be administered as a nasal spray using standard preparation methods to deliver 100 microliters of a 50 mg / ml trefoil peptide spray. For the next 5 consecutive days, the patients were treated by self-administering the nasal spray every 12 hours. Alternatively, the trefoil active material may be used in standard doses of nasal decongestant sprays (eg, 0.05% oxymetazoline hydrochloride).

Embodiment 2

[0098] Example 2: Treatment of allergic rhinitis induced by plant pollen

[0099] During the hay fever season, patients with allergic rhinitis are administered antihistamines such as diphenhydramine, memelonium, cetirizine, or loratadine. In addition, patients are simultaneously administered ITF containing therapeutic doses 15-73 nasal spray formulations. In one example, the composition is a nasal spray using standard preparation methods to deliver 5 mg / ml ITF spray. For the next 5 days, patients were treated by self-administering the nasal spray every 12 hours or as needed. In severe cases, the ITF active material may also be administered with standard dose nasal corticosteroid sprays (eg, beclomethasone propionate, fluticasone, mometasone, or triamcinolone).

Embodiment 3

[0100] Example 3: Treatment following virally prolonged bronchospasm

[0101] In post-viral tracheobronchial epithelial lesions, trefoil-containing materials can be co-formulated with standard doses of inhaled salmeterol formulations into dry powder inhalers, aerosol metered dose inhalers, or as present in ultrasonic or air jet Solution or suspension in nebulizer. Patients continued treatment for at least 72 hours by self-administering the drug every 12 hours.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method of treating respiratory epithelial lesions by topical or systemic administration of intestinal trilobite peptide. The intestinal trilopeptide may be administered alone or in combination with one or more therapeutic agents.

Description

field of invention [0001] The present invention relates to methods and compositions for treating respiratory epithelial lesions, which may be caused, for example, by viral, bacterial, and fungal infections, inflammation, allergens, inhaled organic solvents, particulate matter, or irritating gases. Background of the invention [0002] Upper airway lesions, including external nares to throat, are caused by a variety of local agonists, allergens, and infectious agents. Typically, the agonists produce symptoms of rhinitis or 'runny nose'. However, in cases of severe injury, the tight junctions of the respiratory epithelial mucosa are disrupted in order to facilitate the entry of allergens or infectious agents. [0003] Tracheobronchial lesions (trachea and conducting bronchi reaching the level of the bronchioles of the respiratory tract), often also caused by respiratory infections, agonists, or allergens. Once the tracheobronchial epithelium and tight ju...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/12A61K9/14A61K31/7036A61K38/22A61K45/06A61P11/00C12N1/21C12N15/12
CPCA61K31/7036A61K38/22A61K45/06A61P11/00A61P11/06A61K2300/00
Inventor D·K·波多尔斯基
Owner THE GENERAL HOSPITAL CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com